Drug Target Review Synthetic Biology ebook 2021
Posted: 22 September 2021 | Drug Target Review | No comments yet
In this ebook, discover why CRISPR can aid the development of new drugs via loss-of-function screens and how the field of synthetic biology is likely to evolve within the context of health.
The use of synthetic biology has shown vast promise across early drug discovery and development.
Focusing on CRISPR, Dr Pushpanathan Muthuirulan explores why this technology holds promise to progress pharmacological research. He explains that CRISPR can be used to develop gene-edited cells for drug discovery processes including high-throughput screens.
Dr Jim Collins additionally reveals how synthetic biology approaches can be utilised throughout the life sciences. He also discusses how this area of research is likely to evolve in the future, with regards to therapeutic development and diagnostics.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Included in this ebook:
- CRISPR-Cas9-based gene dropout screens: a powerful platform for drug discovery
Dr Pushpanathan Muthuirulan, Harvard University - The diversity of synthetic biology applications
Dr Jim Collins, MIT and Wyss Institute at Harvard University
